Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04409509 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
DRUG: Placebo

Sponsor

CSL Behring